个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
何雅億，博士，同济大学附属上海市肺科医院主任医师，博士生导师。目前担任同济大学附属上海市肺科医院肿瘤科行政副主任。先后至云南东川人民医院进行扶贫援滇、上海新国博及复兴岛方舱医院新冠救治，美国科罗拉多大学访问学习（PI为国际肺癌研究协会前执行总裁Fred R Hirsch教授）。
YayiHe, PhD./MD., Professor of treatment of Tongji University affiliated ShanghaiPulmonary Hospital, Doctoral supervisor. She is deputy director of Departmentof Oncology of Tongji University affiliated Shanghai Pulmonary Hospital. Shehas gone to People’s Hospital of Dongchuan in Yunnan Province for medical aidand participated in fighting against COVID-19. She used to be a visitingscholar in the University of Colorado (the PI was Prof. Fred R Hirsch, theformer CEO of the International Association for the Study of Lung Cancer).
何雅億主持了国家重点研发计划、工信部“揭榜挂帅”项目、国家自然科学基金（面上及青年）、省部级项目及横向课题10项，以第一/通讯（含共同）在Nature Cancer、Advanced Science、Journal of Thoracic Oncology、Seminarsin Cancer Biology、Journal for Immunotherapy of Cancer、Journal of Hematology & Oncology、Engineering和Acta Pharmaceutica Sinica B等本领域权威期刊发表论文45篇，IF>10的论文15篇，H指数28。参编中英文论著Lung Cancer（副主编，2021）和《肺癌》（副主编，2021）；还参编了《临床研究经典案例分析》（副主编，2021）和《肿瘤靶向治疗及免疫治疗进展》（编委，2020）；应邀参加中国临床肿瘤学年会（CSCO）、美国临床肿瘤学年会（ASCO）、欧洲临床肿瘤学年会（ESMO）、世界肺癌大会（WCLC）和日本肺癌学会年会（JLCS）等学术会议，多次以口头汇报及壁报展示学术成果，获得参会同行的认可。同时，何雅億担任国家自然科学基金委评审专家、CSCO研究基金会评审专家和Translational Lung Cancer Research、《呼吸与危重症医学（英文）》（CMJ PCCM）期刊编委。
Prof. Yayi He has been a leader of 10 projects including National KeyResearch and Development Program, Open Bidding for Selecting the BestCandidates Program of Ministry of Industry and Information Technology of China,programs from National Natural Science Foundation of China (Youth Program andGeneral Program), provincial and ministerial programs and horizontal topicresearch. As first and corresponding author (including co-first andco-corresponding author), she has published 45 papers on leading journal in thefield including Nature Cancer、Advanced Science、Journal of Thoracic Oncology、Seminars in Cancer Biology、Journal for Immunotherapy of Cancer、Journal of Hematology & Oncology、Engineering and Acta Pharmaceutica Sinica B, of which 15 papers’ impact factorswere higher than 10. And the H-score of Prof. Yayi He is 28. She also coedits 4books including Lung Cancer (subeditor, 2021), Lung Cancer (Chinese version,subeditor, 2021), Classic Case Analysis of Clinical Research (Chinese version,subeditor, 2021) and Advances in Tumor Targeted Therapy and Immunotherapy(Chinese version, editorial board member, 2021). She was invited to do oral presentationsor make posters of her studies in Annual Conferences of Chinese Society ofClinical Oncology (CSCO), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (EMSO), World Conference on LungCancer (WCLC) and Japanese Lung Cancer Society (JLCS), which were recognized bythe participating peers. At the same time, Prof. He is review expert ofNational Natural Science Foundation of China and Chinese Society of ClinicalOncology (CSCO) Research Foundation. She is also an editor of Translational Lung Cancer Research and Chinese Medical Journal Pulmonary andCritical Care Medicine.
此外，何雅億作为指南专家组主要秘书参编了2019年《CSCO原发性肺癌诊疗指南》及2020年至2022年《CSCO非小细胞肺癌诊疗指南》；参与了《2019年中国非小细胞肺癌免疫检查点抑制剂治疗专家共识》和《2019年晚期非小细胞肺癌抗血管生成药物治疗中国专家共识》撰写工作。
Furthermore,Prof. Yayi He participated in writing 2019CSCO Guideline for Diagnosis and Treatment of Primary Lung Cancer and2020-2022 CSCO Guideline for Diagnosisand Treatment of Non-small Cell Lung Cancer as principal secretary ofexpert. She also written 2019 ExpertConsensus of Immune Checkpoint Blockade Therapy in Lung Cancer and 2019 Expert Consensus of Anti-angiogenesistherapy in Advanced Non-small Cell Lung Cancer.
何雅億先后入选了中国科协高端科技创新青年智库（2021年）、上海市浦江人才（2017年）、上海市青年拔尖人才计划（2019年）、上海市曙光学者（2021年）、上海医树奖青年科技创新奖（2022年）和上海市银蛇奖（2023年）；2015年获得了国际肺癌研究协会（IASLC）学者奖。
Prof.Yayi He has been awarded high-end science and technology innovation youth thinktank of China Association for Science and Technology (2021), Shanghai PujiangTalent (2017), Shanghai Youth Top Talent (2029), Shanghai Shuguang Scholars(2021), Shanghai Medical Science and Technology Innovation Award for Youth(2022), Shanghai Yinshe Award (2023) and Scholar Award of InternationalAssociation for the Study of Lung Cancer (IASLC) (2015).
团队聚焦“医工交叉”在肺癌精准诊疗中的应用。该团队目前由临床医生、研究生、本科生、多组学人工智能工程师、生物背景基础科研人员以及质谱工程师构成。工科团队积极与江西中医药大学陈焕文教授展开合作，依托其创建的质谱科学与仪器国际联合研究中心、江西省重点实验室开展质谱肺癌早诊国产仪器的研发；分子影像团队积极与苏州大学高明远教授合作，依托苏州大学放射医学与辐射防护国家重点实验室开展诊疗一体化探针及肺癌治疗疗效的影像学监测方法的构建；先进纳米材料团队积极与南京大学顾宁院士合作，将铁基纳米材料应用在肺癌影像评估及治疗中；肺癌基础研究团队积极与中科院季红斌教授合作，依托中科院分子细胞科学卓越创新中心探索详细的肺癌耐药机制，开创逆转耐药的治疗新方案。
1. 肺癌诊疗效果分子评价仪的研制与应用，中国科技部重点研发计划青年科学家项目，200万元，在研
2. 基于仿生级联酶纳米反应器的谷氨酰胺代谢调控策略在KRAS驱动肺癌治疗中的应用及机制研究,国家自然科学基金面上项目，48万元，在研
3. 养阴解毒法联合靶向辅助治疗非小细胞肺癌术后辅助的临床研究，癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项课题负责人，193万，在研
4. 肿瘤微环境异质性定量动态可视化及免疫治疗疗效预测监测诊疗策略研究，国家自然科学基金面上项目，54万元，在研
5. 肺癌精准免疫治疗模型构建，上海市教育委员会，上海市教育发展基金会，15万元，在研
6. 一线使用抗PD-1/PD-L1单克隆抗体和化疗对照抗PD-1/PD-L1单克隆抗体和化疗联合经支气管镜微波介入治疗晚期中央型非小细胞肺癌患者的疗效和安全性的随机对照、前瞻性临床研究，上海市卫健委临床研究项目，10万元，在研
7. 小细胞一线化疗耐药后精准治疗策略探索（医企融合创新成果转化专项），上海申康医院发展中心，40万元，在研
8. 四氧化三铁纳米颗粒在肺癌影像中的应用研究（工信部揭榜挂帅项目），中华人民共和国工业和信息化部，不设资助金额，在研
9. EGFR突变型NSCLC通过外泌体促进脑星形胶质细胞VEGF分泌的机制研究，国家自然科学基青年项目，21万元，结题
1. 肺癌诊疗效果分子评价仪的研制与应用，中国科技部重点研发计划青年科学家项目，200万元，在研
2. 基于仿生级联酶纳米反应器的谷氨酰胺代谢调控策略在KRAS驱动肺癌治疗中的应用及机制研究,国家自然科学基金面上项目，48万元，在研
3. 养阴解毒法联合靶向辅助治疗非小细胞肺癌术后辅助的临床研究，癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项课题负责人，193万，在研
1. Therapeutic targeting of themevalonate-geranylgeranyl diphosphate pathway with statins overcomeschemotherapy resistance in small cell lung cancer; Nature cancer. 2022 May;3(5):614-628.
2. Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG-3 and PD-L1. Adv Sci (Weinh). 2025;12(1):e2404231.
3. cGAS-STING, an important pathway in cancerimmunotherapy; Journal of hematology& oncology. 2020 Jun 22;13(1):81.
4. Mutational profile evaluates response and survival to first-linechemotherapy in lung cancer; Advanced science (Weinh). 2020 Dec 30;8(4):2003263.
5. Microbes in lung cancer initiation, treatment,and outcome: Boon or bane? Seminars in cancerbiology. 2021 May 21;S1044-579X(21)00154-1.
6. Mechanisms of progression and heterogeneity in multiplenodules of lung adenocarcinoma; SmallMethods. 2021 Jun;5(6):e2100082.
7. Prediction of Driver Gene Matching in Lung Cancer NOG/PDX Models Based on Artificial Intelligence; Engineering. 2022 August; 15:102-114.
8. Human leukocyte antigen class II-based immunerisk model for recurrence evaluation in stage I-III small cell lung cancer; Journal for immunotherapy of cancer. 2021 Aug;9(8):e002554.
9. Galectin-9-based immune risk score model helps topredict relapse in stage I-III small cell lung cancer. Journal for immunotherapy of cancer.2020;8(2):e001391.
10. Genomic and transcriptional alterations infirst-line chemotherapy exert a potentially unfavorable influence on subsequentimmunotherapy in NSCLC; Theranostics.2021 May 13;11(14):7092-7109.
11. Smoking related environmental microbes affectingthe pulmonary microbiome in Chinese population; The Science of the total environment. 2022 Jul 10;829:154652.
文件上传中...
同济大学